Cancer Research Technology moves into newly completed Jonas Webb Building


19-04-2013

Babraham Bioscience Technologies (BBT) has announced that Cancer Research Technology Limited (CRT), the cancer-focused technology development and commercialisation arm of Cancer Research UK, has moved its Cambridge drug discovery activity into a new chemistry-focused building on the Babraham Research Campus. The new building has been named ‘The Jonas Webb Building’.

The Babraham Research Campus has established itself as a hub of bioscience innovation at the heart of the Cambridge cluster and, with the arrival of CRT, is now home to 45 innovative biomedical companies. The Jonas Webb Building offers around 16,000 sq ft of lettable space, which will include 24 fume hoods, open plan bench space, offices and meeting rooms. CRT has taken a lease on half of the building, which will accommodate 27 of their researchers working in the area of cancer therapeutics.  A number of companies are progressing interest with the remainder of the building.

Derek Jones the CEO of Babraham Bioscience Technologies the organisation that manages the campus and its development said, “We welcome CRT to be part of the Babraham community, a dynamic co-location of academic research from the world-class Babraham Institute with commercial organisations on the campus, developing the therapies, science and technologies to treat human disease.  Our role at the campus is help support bio-enterprise both with organisations located at the campus, but also the wider Cambridge cluster, including our relationship with Pfizer and Medimmune, Cambridge University and One Nucleus.  I know that CRT is keen to be active members of the campus, and I hope their arrival will encourage further interest from other organisations in the facilities and resources we can offer here.”

Professor Michael Wakelam, Director of the Babraham Institute, said, "The arrival of CRT provides an opportunity to build upon the collaborative links that already exist between some of our research group leaders and CRT and Cancer Research UK scientists. We expect that this will promote further collaborative initiatives benefiting from the world leading research strengths of both organisations."

Dr Keith Blundy, Chief Executive of Cancer Research Technology, said, “We’re delighted to move into the Jonas Webb Building, which will provide a fertile scientific environment for the life-saving research carried out by our world-class drug discovery experts.”


Babraham Bioscience Technologies Ltd is the commercial arm of the Babraham Institute, which undertakes international quality research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. BBT promotes, supports and encourages academic and commercial biomedical research locally, regionally and nationally. BBT is responsible for managing the Babraham Research Campus’ Bioincubator, currently home to over 40 early-stage biomedical companies. BBT brings together all the elements to support innovation and enable the successful exploitation of research in the biomedical sector based on technologies emanating from the Babraham Institute and bioventures relocating to the campus. BBT has taken a prominent role regionally, initiating and leading partnerships to promote knowledge and skills flow and has established a reputation for successfully translating innovative science into viable business opportunities through partnerships for wealth creation. Website: www.babraham.com


About Cancer Research Technology

Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research. Further information about CRT can be found at www.cancertechnology.com




*******

Contact details:
Dr Claire Cockcroft
Head, External Relations
The Babraham Institute
Email: claire.cockcroft@babraham.ac.uk
Tel: +44 (0)1223 496260
Mobile: +44 (0)7786 335978

Derek Jones, Chief Executive
Babraham Bioscience Technologies Limited
Email: derek.jones@babraham.co.uk
Tel: +44 (0)1223 496262

Babraham Research Campus
Cambridge
CB22 3AT
http://www.babraham.com

_________________________________________________



 

Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

Babraham Bioscience Technologies Limited